
1K
Downloads
13
Episodes
Welcome to Phacilitate Talks, a socially distanced chat show for the advanced therapies community, getting you close to advanced therapies experts and asking them the big questions. Get your inspiration fix straight to your inbox by becoming a Phacilitate member. Get ready to discuss, debate and deliberate today‘s most important issues...
Episodes

Friday Aug 27, 2021
The Future of Cell and Gene Therapy with Bruce Levine and Audrey Greenberg
Friday Aug 27, 2021
Friday Aug 27, 2021
Season 2 of Phacilitate Talks kicks off with a bang as Bruce Levine and Audrey Greenberg explore key questions associated with building capacity, acquiring talent and looking ahead in a post-pandemic world.
Welcome to season 2 of Phacilitate Talks! This season, we have left the pandemic norm and returned to offices, in-person meetings and even live events!
Watch the full video via the Phacilitate website: https://bit.ly/3kn7Naf
As we begin our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.
Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG
In this first episode, Anthony and Georgi are joined by Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, and Audrey Greenberg, Co-Founder, Discovery Labs & Centre for Breakthrough Medicines, as they discuss the future of cell and gene therapy.
The group discusses different models for CDMO capacity expansion, acquiring appropriate talent to manage expansion opportunities and the resulting ripple effect and rapid development in the field following multiple, recent high-profile mergers and acquisitions.
*Bonus footage – “Are you talking to the FDA yet?”
As a special treat for launching the new season, we have shared an extra segment exclusive to watch on the Phacilitate website.
In this bonus clip, Anthony, Audrey and Bruce discuss the process (and best practice) for engaging the FDA in the product development pipeline for cell and gene therapies, sharing top tips and exclusive insights from their combined experience in cell and gene therapy development.
The group discusses the idea that “perfect is the enemy of good” – a quote attributed to Peter Marks (CBER, FDA) from a recent ISCT meeting – outlining key issues associated with attitudes and approaches associated with the idea of perfection with cell and gene therapies, as well as the requirements for regulating them.
Watch the bonus footage here: https://bit.ly/3krMrbI
QUICK LINKS
- Bruce Levine: https://bit.ly/3DdC5oC
- Audrey Greenberg: https://bit.ly/3DhDxpR
- Anthony Davies: https://bit.ly/3B7EQpJ
- Christina Fuentes: https://bit.ly/2YSihaL
- Georgi Makin: https://bit.ly/2Wg7Qgl
The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers.
This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.